Y Intercept Hong Kong Ltd Buys 12,617 Shares of Ultragenyx Pharmaceutical Inc.

RARE Stock  USD 38.62  1.40  3.50%   
About 76 percent of Ultragenyx's shareholders are selling. The analysis of the overall investor sentiment regarding Ultragenyx suggests that quite a large number of traders are terrified. The current market sentiment, together with Ultragenyx's historical and current headlines, can help investors time the market. In addition, many technical investors use Ultragenyx stock news signals to limit their universe of possible portfolio assets.
  
Y Intercept Hong Kong Ltd raised its position in shares of Ultragenyx Pharmaceutical Inc. by 193.1 percent in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 19,151 shares of the biopharmaceutical companys stock after purchasing an additional

Read at thelincolnianonline.com
news
  

Ultragenyx Current Investor Sentiment

Comfort Level 24

 Terrified

 
Panic
 
Confidence
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Ultragenyx's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Ultragenyx.

Ultragenyx Investor Sentiment by Other News Outlets

Investor sentiment, mood or attitude towards Ultragenyx can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.

Ultragenyx Historical Investor Sentiment

Investor biases related to Ultragenyx's public news can be used to forecast risks associated with an investment in Ultragenyx. The trend in average sentiment can be used to explain how an investor holding Ultragenyx can time the market purely based on public headlines and social activities around Ultragenyx. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Ultragenyx's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Ultragenyx and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Ultragenyx news discussions. The higher the estimate score, the more favorable the investor's outlook on Ultragenyx.

Ultragenyx Maximum Pain Price Across May 16th 2025 Option Contracts

Ultragenyx's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Ultragenyx close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Ultragenyx's options.

Ultragenyx Fundamental Analysis

We analyze Ultragenyx's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ultragenyx using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ultragenyx based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Working Capital

Working Capital Comparative Analysis

Ultragenyx is currently under evaluation in working capital category among its peers. Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .

Ultragenyx Potential Pair-trading

One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ultragenyx stock to make a market-neutral strategy. Peer analysis of Ultragenyx could also be used in its relative valuation, which is a method of valuing Ultragenyx by comparing valuation metrics with similar companies.

Peers

Ultragenyx Related Equities

AMLXAmylyx Pharmaceuticals   7.20   
0%
87.0%
UTHRUnited Therapeutics   2.67   
0%
32.0%
KURAKura Oncology   2.26   
0%
27.0%
ARVNArvinas   1.22   
0%
14.0%
INCYIncyte   1.00   
0%
12.0%
RVMDRevolution Medicines   0.03   
1.0%
0%
ABOSAcumen Pharmaceuticals   0.80   
9.0%
0%
APLSApellis Pharmaceuticals   1.11   
13.0%
0%
ALNYAlnylam Pharmaceuticals   1.45   
17.0%
0%
CRNXCrinetics Pharmaceuticals   2.43   
29.0%
0%
TERNTerns Pharmaceuticals   3.86   
47.0%
0%
DAWNDay One   4.73   
57.0%
0%
INZYInozyme Pharma   6.50   
79.0%
0%
XFORX4 Pharmaceuticals   7.89   
96.0%
0%
PDSBPDS Biotechnology   8.21   
100.0%
0%

Complementary Tools for Ultragenyx Stock analysis

When running Ultragenyx's price analysis, check to measure Ultragenyx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Ultragenyx is operating at the current time. Most of Ultragenyx's value examination focuses on studying past and present price action to predict the probability of Ultragenyx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Ultragenyx's price. Additionally, you may evaluate how the addition of Ultragenyx to your portfolios can decrease your overall portfolio volatility.
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Commodity Channel
Use Commodity Channel Index to analyze current equity momentum